Literature DB >> 8032341

Clinical and biochemical aspects of uric acid overproduction.

J García Puig1, F A Mateos.   

Abstract

Purine nucleotides are synthesized and degraded through a regulated series of reactions which end in the formation of uric acid. Increased uric acid synthesis may be the result of two major pathophysiological disorders: increased de novo purine synthesis and enhanced purine nucleotide degradation, both of which may be the result of an increased or decreased enzyme activity. In addition, some conditions and disorders associated with uric acid overproduction have been recognized as the result of increased ATP degradation or decreased synthesis of ATP. The clinical manifestations of the diseases leading to excess uric acid synthesis are heterogenous, but symptoms related to uric acid overproduction are always secondary to the precipitation of crystals in soft tissues, joints, and the kidney excretory system. In clinical practice, serum urate concentration and urinary uric acid excretion are used to assess uric acid synthesis, taking into account that a purine-rich diet can be a confounding variable. Quantification of uric acid precursors, such as adenosine, inosine, guanosine, hypoxanthine, and xanthine, in biological fluids and intracellular nucleotides has provided further insight into the metabolic disturbances underlying disorders associated with uric acid overproduction. Additional studies are necessary to define precisely the metabolic derangement in idiopathic uric acid overproduction and to assess fully the consequences of increased purine nucleotide degradation, such as free-radical formation, increased adenosine synthesis, and reduced synthesis of signal transducers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032341     DOI: 10.1007/bf01880655

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  101 in total

1.  Distinct neurological syndrome in two brothers with hyperuricaemia.

Authors:  H J Christen; F Hanefeld; J A Duley; H A Simmonds
Journal:  Lancet       Date:  1992-11-07       Impact factor: 79.321

2.  Uric acid metabolism in psoriasis.

Authors:  A Z EISEN; J E SEEGMILLER
Journal:  J Clin Invest       Date:  1961-08       Impact factor: 14.808

3.  Gout and blood dyscrasias.

Authors:  J H TALBOTT
Journal:  Medicine (Baltimore)       Date:  1959-05       Impact factor: 1.889

4.  Gout with purine overproduction due to increased phosphoribosylpyrophosphate synthetase activity.

Authors:  M A Becker; L J Meyer; J E Seegmiller
Journal:  Am J Med       Date:  1973-08       Impact factor: 4.965

Review 5.  Hypoxanthine as an indicator of hypoxia: its role in health and disease through free radical production.

Authors:  O D Saugstad
Journal:  Pediatr Res       Date:  1988-02       Impact factor: 3.756

6.  Identification of the causes of persistent hyperuricaemia.

Authors:  B T Emmerson
Journal:  Lancet       Date:  1991-06-15       Impact factor: 79.321

7.  Enzyme defect in primary gout.

Authors:  H G Hers; G Van Den Berghe
Journal:  Lancet       Date:  1979-03-17       Impact factor: 79.321

8.  Mutant feedback-resistant phosphoribosylpyrophosphate synthetase associated with purine overproduction and gout. Phosphoribosylpyrophosphate and purine metabolism in cultured fibroblasts.

Authors:  E Zoref; A De Vries; O Sperling
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

9.  Xanthine oxidase activity in human tissues and its inhibition by allopurinol (4-hydroxypyrazolo[3,4-d] pyrimidine).

Authors:  R W Watts; J E Watts; J E Seegmiller
Journal:  J Lab Clin Med       Date:  1965-10

10.  Metabolic basis for disorders of purine nucleotide degradation.

Authors:  I H Fox
Journal:  Metabolism       Date:  1981-06       Impact factor: 8.694

View more
  6 in total

1.  Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update.

Authors:  Claudio Borghi; Justyna Domienik-Karłowicz; Andrzej Tykarski; Krystyna Widecka; Krzysztof J Filipiak; Miłosz J Jaguszewski; Krzysztof Narkiewicz; Giuseppe Mancia
Journal:  Cardiol J       Date:  2021-01-13       Impact factor: 2.737

2.  AMP-deaminase from normal and cirrhotic human liver: a comparative study.

Authors:  Paweł Dutka; Magdalena Szydłowska; Zygmunt Chodorowski; Iwona Rybakowska; Gabriela Nagel-Starczynowska; Krystian Kaletha
Journal:  Mol Cell Biochem       Date:  2004-07       Impact factor: 3.396

3.  Decreased extra-renal urate excretion is a common cause of hyperuricemia.

Authors:  Kimiyoshi Ichida; Hirotaka Matsuo; Tappei Takada; Akiyoshi Nakayama; Keizo Murakami; Toru Shimizu; Yoshihide Yamanashi; Hiroshi Kasuga; Hiroshi Nakashima; Takahiro Nakamura; Yuzo Takada; Yusuke Kawamura; Hiroki Inoue; Chisa Okada; Yoshitaka Utsumi; Yuki Ikebuchi; Kousei Ito; Makiko Nakamura; Yoshihiko Shinohara; Makoto Hosoyamada; Yutaka Sakurai; Nariyoshi Shinomiya; Tatsuo Hosoya; Hiroshi Suzuki
Journal:  Nat Commun       Date:  2012-04-03       Impact factor: 14.919

4.  Serum uric acid level as a cardio-cerebrovascular event risk factor in middle-aged and non-obese Chinese men.

Authors:  Zhi-Jun Li; Chen-Ju Yi; Jing Li; Na Tang
Journal:  Oncotarget       Date:  2017-04-11

5.  Blood cell transcript levels in 5-year-old children as potential markers of breastfeeding effects in those small for gestational age at birth.

Authors:  Julio Alvarez-Pitti; Maria Amparo Ros-Forés; Ana Bayo-Pérez; Mariona Palou; Empar Lurbe; Andreu Palou; Catalina Picó
Journal:  J Transl Med       Date:  2019-05-07       Impact factor: 5.531

6.  Assessment of Hematological and Biochemical parameters with extended D-Ribose ingestion.

Authors:  John Seifert; Angela Frelich; Linda Shecterle; John St Cyr
Journal:  J Int Soc Sports Nutr       Date:  2008-09-15       Impact factor: 5.150

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.